Aliases for SLC29A1 Gene
- Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 1 2 3
- ENT1 3 4 6
- Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter 3 4
- Solute Carrier Family 29 (Nucleoside Transporters), Member 1 2 3
- Equilibrative NBMPR-Sensitive Nucleoside Transporter 3 4
- Solute Carrier Family 29 Member 1 3 4
External Ids for SLC29A1 Gene
Previous Symbols for SLC29A1 Gene
This gene is a member of the equilibrative nucleoside transporter family. The gene encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium. The protein is categorized as an equilibrative (as opposed to concentrative) transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced variants, encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008]
GeneCards Summary for SLC29A1 Gene
SLC29A1 (Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 1) is a Protein Coding gene. Diseases associated with SLC29A1 include pancreas adenocarcinoma and pancreatic cancer. Among its related pathways are RNA Polymerase I Promoter Opening and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. GO annotations related to this gene include nucleoside transmembrane transporter activity. An important paralog of this gene is SLC29A3.
UniProtKB/Swiss-Prot for SLC29A1 Gene
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs)
Nucleoside transporters are divided into two families; the Na+-dependent solute carrier family 28 (SLC28) and the equilibrative solute carrier family 29 (SLC29). SLC28 family transporters (CNT1-3) display subtype-selective expression patterns; CNT1 is localized primarily to epithelial tissue whereas CNT2 and CNT3 have more widespread distributions. SLC29 family transporters (ENT1-4) are glycosylated proteins, localized to the plasma and mitochondrial membranes. They are expressed in the heart, brain, mammary gland, erythrocytes and placenta, and also in fetal liver and spleen. They mediate nucleoside influx and efflux and exhibit highest affinity for adenosine. CNT and ENT transporters play critical roles in nucleoside salvage pathways where they mediate the first step of nucleotide biosynthesis. In addition, these transporters work in concert to terminate adenosine signaling and are vital determinants in the response to a variety of anticancer and antiviral treatments, as they modulate the entry of these nucleoside analogs into target tissues.